Understanding the relationship between age and thyroid cancer

Oncologist

Volumn 14, Issue 3, 2009, Pages 216-221

  Haymart, Megan R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Age; Cancer stage; Prognostic indicators; Thyroid cancer

Indexed keywords

LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

AGE DISTRIBUTION; AGING; ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HEART ARRHYTHMIA; HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STANDARD; SURVIVAL RATE; THYROID CANCER; THYROIDECTOMY; TISSUE MICROARRAY; TREATMENT PLANNING;

ADULT; AGE FACTORS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63849102122     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0194     Document Type: Article

References (35)

1. Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-2648.
2. Gilliland FD, Hunt WC, Morris DM et al. Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-573.
3. Greene FL, Page DL, Fleming ID et al., eds. Thyroid. In: American Joint Committee on Cancer: Cancer Staging Manual, Sixth Edition. New York:Springer-Verlag, 2002:77-87.
4. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-239.
5. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463.
6. Davies L, Welch HG. Increasing incidence ofthyroid cancer in the United States, 1973-2002. JAMA2006;295:2164-2167.
7. Faggiano A, Coulot J, Bellon N et al. Age-dependent variation of follicular size and expression ofiodine transporters in human thyroid tissue. J Nucl Med 2004;45:232-237.
8. Saad AG, Kumar S, Ron E et al. Proliferative activity of human thyroid cells in various age groups and its correlation with risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 2006;91:2672-2677.
9. Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Relat Cancer 2005;12:773-803.
10. Miccoli P, Minuto MN, Ugolini C et al. Papillary thyroid cancer: Pathological parameters as prognostic factors in different classes of age. Otolaryngol Head Neck Surg 2008;138:200-203.
11. Ronga G, Filesi M, Montesano T et al. Lung metastases from differentiated thyroid carcinoma: A 40 years' experience. Q J Nucl Med Mol Imaging 2004;48:12-19.
12. Ringel MD, Anderson J, Souza SL et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001;14:289-296.
13. Lee JH, Lee ES, KimYS. Clinicopathologic significance ofBRAF V600E mutation in papillary carcinomas of the thyroid: A meta-analysis. Cancer 2007;110:38-46.
14. Wang J, Knauf JA, Basu S et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 2003;17:1425-1436.
15. Sampson E, Brierley JD, LeLW et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis atdiagnosis. Cancer 2007;110:1451-1456.
16. Jung TS, Kim TY, Kim KW et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants ofpapillary thyroid carcinoma. Endocrine J 2007;54:265-274.
17. Lin JD, Liou MJ, Chao TC et al. Prognostic variables ofpapillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocr RelatCancer 1999;6:109-115.
18. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007;92:4575-4582.
19. Xing M, Usadel H, Cohen Y et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: A marker of malignancy and a cause ofgene silencing. Cancer Res 2003;63:2316-2321.
20. Haymart MR, Repplinger DJ, Leverson GE et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008;93:809-814.
21. Boelaert K, Horacek J, Holder RL et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006;91:4295-4301.
22. Haymart MR, Glinberg SL, Liu J et al. Higher serum TSH inthyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 2008 Dec 3 [Epub ahead of print].
23. Zaydfudim V, Feurer ID, Griffin MR et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery2008;144:1070-1078.
24. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109 -142.
25. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379.
26. Grodski S, Cornford L, Sywak M et al. Routine level VI lymph node dissection for papillary thyroid cancer: Surgical technique. ANZ J Surg 2007; 77:203-208.
27. Scheumann GF, Gimm O, Wegener G et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994;18:559-568.
28. Bonnet S, Hartl D, Leboulleux S et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: Implications for radioiodine treatment. J Clin Endocrinol Metab 2008 Dec 30 [Epub ahead ofprint].
29. Chow S-M, Yau S, Kwan C-K et al. Local and regional control in patients with papillary thyroid carcinoma: Specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC Sixth Edition. Endocr Relat Cancer 2006;13:1159-1172.
30. Brown AP, Chen J, Hitchcock YJ et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-515.
31. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-932.
32. Barbaro D, Boni G, Meucci G et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role ofiodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-4115.
33. Luster M, Lippi F, Jarzab B et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: A comprehensive review. Endocr Relat Cancer 2005;12:49-64.
34. Tuttle RM, Brokhin M, Omry G et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-770.
35. Jonklaas J, Sarlis NJ, Litofsky D et al. Outcomes ofpatients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16: 1229-1242.